BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 41,666 shares of the firm’s stock in a transaction dated Monday, October 17th. The shares were sold at an average price of $84.39, for a total transaction of $3,516,193.74. Following the completion of the transaction, the chief executive officer now directly owns 365,034 shares in the company, valued at approximately $30,805,219.26. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Friday, October 14th, Jean Jacques Bienaime sold 64,125 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $86.96, for a total transaction of $5,576,310.00.
  • On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $93.65, for a total transaction of $4,975,156.25.
  • On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $95.34, for a total transaction of $13,096,665.12.
  • On Tuesday, August 16th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $91.49, for a total transaction of $3,812,022.34.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down 1.26% during trading on Wednesday, reaching $84.32. 749,430 shares of the company were exchanged. The stock’s 50 day moving average is $94.02 and its 200 day moving average is $89.71. BioMarin Pharmaceutical Inc. has a 1-year low of $62.12 and a 1-year high of $118.48. The company’s market capitalization is $13.78 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($2.61) EPS for the quarter, missing the consensus estimate of ($0.52) by $2.09. The company earned $300.10 million during the quarter, compared to analysts’ expectations of $278.75 million. BioMarin Pharmaceutical had a negative return on equity of 11.99% and a negative net margin of 54.53%. BioMarin Pharmaceutical’s revenue was up 20.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.51) EPS. Equities analysts anticipate that BioMarin Pharmaceutical Inc. will post ($3.95) earnings per share for the current year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Several equities research analysts have recently issued reports on the stock. William Blair set a $116.00 price target on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Thursday, July 28th. Robert W. Baird set a $115.00 price target on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Saturday. Vetr upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $110.24 price target for the company in a research note on Tuesday, August 2nd. Wedbush restated a “neutral” rating and set a $104.00 price target (down previously from $108.00) on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 6th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 7th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. BioMarin Pharmaceutical has an average rating of “Buy” and an average price target of $118.31.

A number of large investors have recently modified their holdings of the company. Prudential Financial Inc. raised its stake in shares of BioMarin Pharmaceutical by 31.2% in the first quarter. Prudential Financial Inc. now owns 141,570 shares of the company’s stock valued at $11,677,000 after buying an additional 33,700 shares during the last quarter. NN Investment Partners Holdings N.V. bought a new stake in shares of BioMarin Pharmaceutical during the first quarter valued at approximately $1,327,000. Aviva PLC raised its stake in shares of BioMarin Pharmaceutical by 1.2% in the first quarter. Aviva PLC now owns 78,847 shares of the company’s stock valued at $6,503,000 after buying an additional 924 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioMarin Pharmaceutical by 4.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,127 shares of the company’s stock valued at $505,000 after buying an additional 282 shares during the last quarter. Finally, State Street Corp raised its stake in shares of BioMarin Pharmaceutical by 5.6% in the first quarter. State Street Corp now owns 3,286,743 shares of the company’s stock valued at $271,074,000 after buying an additional 175,733 shares during the last quarter. 93.08% of the stock is owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.